阿来替尼在ALK阳性NSCLC伴症状性或大块中枢神经系统转移患者中的疗效
这项回顾性研究纳入19例晚期ALK阳性NSCLC伴大块(≥1 cm)或症状性中枢神经系统转移且接受阿来替尼治疗的患者,评估其颅内疗效。15例基线有可测量颅内病灶者颅内客观缓解率为73.3%,颅内疾病控制率为100.0%,中位颅内缓解持续时间为19.3个月;8例有颅内转移相关症状者用药后均获临床改善。
要点
- 15例可评估患者颅内客观缓解率为73.3%(95%CI 44.9%-92.2%),颅内疾病控制率为100.0%(95%CI 78.2%-100.0%)。
- 中位颅内缓解持续时间为19.3个月(95%CI 14.3个月-不可评估)。
- 8例有中枢神经系统转移相关症状者开始阿来替尼治疗后均获临床改善。
核心结论
- 阿来替尼在ALK阳性NSCLC伴未经治疗的症状性或大块脑转移患者中显示出有意义的颅内疗效。
研究设计与样本
- 回顾性研究,纳入19例晚期ALK阳性NSCLC伴大块(定义为≥1 cm)或症状性中枢神经系统转移并接受阿来替尼治疗的患者。
- 通过查阅病历和影像学资料确定治疗结局,颅内疗效按改良实体瘤疗效评价标准1.1版评估。
主要发现
- 19例患者中15例(79%)基线有可测量颅内病灶并可评估疗效,其颅内客观缓解率为73.3%(95%CI 44.9%-92.2%),颅内疾病控制率为100.0%(95%CI 78.2%-100.0%),中位颅内缓解持续时间为19.3个月(95%CI 14.3个月-不可评估)。
- 18例基线有可测量和/或不可测量颅内病灶的可评估患者中,颅内客观缓解率为72.2%(95%CI 46.5%-90.3%),颅内疾病控制率为100.0%(95%CI 81.5%-100.0%),中位颅内缓解持续时间为17.1个月(95%CI 14.3个月-不可评估)。
- 8例有中枢神经系统转移相关症状的患者在开始阿来替尼治疗后均获临床改善。
- 6例患者(32%)最终需要挽救性脑放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Central nervous system (CNS) metastases represent a significant source of morbidity and mortality for patients with ALK tyrosine kinase gene (ALK)-positive NSCLC. Alectinib has demonstrated robust CNS activity in both crizotinib-naive and crizotinib-resistant settings. However, the CNS efficacy of alectinib has not been established in patients with untreated symptomatic, large CNS metastases. METHODS: In this retrospective study, patients were eligible if they had advanced ALK-positive NSCLC with large (defined as ≥1 cm) or symptomatic CNS metastases and received alectinib. Medical records and radiographic imaging were reviewed to determine treatment outcomes. CNS efficacy was assessed per the modified Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: Of the 19 patients, 15 (79%) had measurable CNS disease at baseline and were evaluable for response. The CNS objective response rate in these patients was 73.3% (95% confidence interval [CI]: 44.9%-92.2%), the CNS disease control rate was 100.0% (95% CI: 78.2%-100.0%), and the median CNS duration of response was 19.3 months (95% CI: 14.3 months-not evaluable). In 18 evaluable patients with measurable and/or nonmeasurable baseline CNS disease, the CNS objective response rate was 72.2% (95% CI: 46.5%-90.3%), the CNS disease control rate was 100.0% (95% CI: 81.5%-100.0%), and the median CNS duration of response was 17.1 months (95% CI: 14.3 months-not evaluable). All eight patients with symptoms attributable to CNS metastases had clinical improvement upon starting alectinib therapy. Six patients (32%) eventually required salvage brain radiotherapy. CONCLUSIONS: Alectinib demonstrated meaningful CNS efficacy in patients with ALK-positive NSCLC with untreated symptomatic or large brain metastases.
引用
- Lin JJ, Jiang GY, Joshipura N, et al. Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases. J Thorac Oncol. 2018. PMID: 30529198. doi:10.1016/j.jtho.2018.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。